H.R.2483 — SUPPORT for Patients and Communities Reauthorization Act of 2025
House Roll Call
H.R.2483
| Bill | H.R.2483 — SUPPORT for Patients and Communities Reauthorization Act of 2025 |
|---|---|
| Vote question | On Passage |
| Vote type | Yea-and-Nay |
| Result | Passed |
| Totals | Yea 366 / Nay 57 / Present 0 / Not Voting 9 |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| R | 188 | 27 | 0 | 5 |
| D | 178 | 30 | 0 | 4 |
| I | 0 | 0 | 0 | 0 |
Research Brief
On Passage
Bill Analysis
The SUPPORT for Patients and Communities Reauthorization Act of 2025 (HR 2483) aims to enhance and extend various initiatives established under previous legislation to combat the opioid crisis and improve patient care. This law reauthorizes critical programs and funding mechanisms to address substance use disorders, particularly opioid addiction, and to support affected communities.
Key provisions of the Act include the reauthorization of funding for the Substance Abuse and Mental Health Services Administration (SAMHSA) to support state and local treatment programs, prevention initiatives, and recovery support services. The Act also strengthens the Comprehensive Addiction and Recovery Act (CARA) by expanding access to medication-assisted treatment (MAT) and promoting the use of naloxone, an opioid overdose reversal drug.
The legislation allocates resources for the establishment of new grant programs aimed at enhancing the capacity of healthcare providers to deliver evidence-based treatment for substance use disorders. It also mandates the development of educational resources and training for healthcare professionals to improve their understanding of addiction and treatment options.
Beneficiaries of the Act include individuals struggling with substance use disorders, healthcare providers, and community organizations involved in prevention and recovery efforts. The Act also imposes regulations on pharmaceutical companies to ensure responsible prescribing practices and to mitigate the risks associated with opioid medications.
Key timelines include the immediate implementation of reauthorized programs and the establishment of new grant opportunities within the fiscal year following the law’s enactment. The law emphasizes ongoing evaluation and reporting requirements to assess the effectiveness of funded programs and initiatives.
In summary, HR 2483 represents a comprehensive approach to addressing the opioid epidemic, focusing on prevention, treatment, and recovery, while ensuring accountability among stakeholders involved in combating substance use disorders.
Yea (366)
K
Ken Calvert
J
Jason Crow
L
Lloyd Doggett
S
Scott Franklin
J
John Garamendi
M
Mark Green
J
John Mannion
L
Lucy McBath
L
Lisa McClain
J
John Rutherford
D
David Schweikert
P
Pete Sessions
E
Eric Swalwell
R
Rashida Tlaib
D
Debbie Wasserman Schultz
Nay (57)
N
Nydia Velázquez
